Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages

To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI], 0.77–0.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI, 0.81–0.94), and COVID-19 mortality (aHR = 0.85; 95% CI, 0.71–1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages.

**Keywords.** COVID-19; SARS-CoV-2; AY.4.2; VUI-21OCT-01; hospitalization; mortality.

A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta (Pango lineage B.1.617.2; https://cov-lineages.org) variant sublineage, AY.4.2, slowly increased in prevalence among coronavirus disease 2019 (COVID-19) cases in England, from <0.01% in early June to 20.3% in the week commencing 15 November 2021 [1]. After preliminary analyses suggested that AY.4.2 might have a small transmission advantage compared to non-AY.4.2 delta [1], AY.4.2 was designated a variant under investigation (VUI-21OCT-01) by the UK Health Security Agency (UKHSA) on 20 October 2021 [1]. It is unknown whether AY.4.2 is associated with a differently severe COVID-19 than non-AY.4.2 delta. We therefore investigated the relative severity of AY.4.2 compared to other delta cases using a retrospective cohort study.

**METHODS**

The study population comprised COVID-19 cases in England with a first positive specimen between 21 June and 7 November 2021 who were infected with AY.4.2 or a non-AY.4.2 delta variant based on whole-genome sequencing. Data on these cases were linked to national hospital care and mortality datasets on 1 December 2021. Before the week commencing 21 June, <0.2% of sequencing-confirmed delta cases had the AY.4.2 sublineage [1]; during the inclusion period the prevalence of AY.4.2 among new sequencing-confirmed cases increased from 0.2% to 15% (Supplementary Figure 1). The data linkage, inclusion criteria, outcome and confounder data sources and definitions, and the analysis strategy have been described in a recent article [2].

Using stratified Cox regression models, we estimated hazard ratios (HRs) of hospital admission and hospital admission or emergency care attendance within 14 days, and of COVID-19 or all-cause mortality within 28 days after a first positive COVID-19 test. These models were stratified for week of specimen and lower tier local authority of residence, to account for reporting delays and unobserved confounders that may differ by calendar time and locality. Regression adjustment was used for age and index of multiple deprivation rank (each modelled using restricted cubic splines with 4 knots), date of specimen reporting delays and unobserved confounders that may differ by calendar time and locality. Regression adjustment was used for age and index of multiple deprivation rank (each modelled using restricted cubic splines with 4 knots), date of specimen...
RESULTS

Characteristics

A total of 28,736 AY.4.2 cases and 492,301 non-AY.4.2 delta cases were identified through the data linkage and included in the study. The age distribution was similar between AY.4.2 cases (median 31 years, interquartile range 13–48) and non-AY.4.2 delta cases (median 30 years, interquartile range 15–48). A slightly greater proportion of AY.4.2 cases than non-AY.4.2 delta cases resided in South-East England and in less-deprived areas. As expected, the AY.4.2 cases tended to have tested positive in more recent weeks (Supplementary Table 1).

Hospitalization and Mortality

After adjustment for confounders, the risks of hospital admission (HR = 0.85; 95% confidence interval [CI], .77–.94) and hospital admission or emergency care attendance (HR = 0.87; 95% CI, .81–.94) were lower for AY.4.2 compared to non-AY.4.2 delta cases. There was no significant difference in the risk of COVID-19 mortality (HR = 0.85; 95% CI, .71–1.03) but the risk of all-cause mortality was lower (HR = 0.82; 95% CI, .69–.98) for AY.4.2 compared to non-AY.4.2 delta variant cases (Table 1). For the outcome hospital admission, the difference in risk was somewhat more pronounced for unvaccinated AY.4.2 versus non-AY.4.2 cases (HR = 0.79; 95% CI, .65–.95) than for vaccinated AY.4.2 versus non-AY.4.2 cases (HR = 0.89; 95% CI, .79–1.01); otherwise, the results for AY.4.2 versus non-AY.4.2 delta cases were similar in the subgroups defined by vaccination status or symptom status (Table 2). The sensitivity analysis exploring alternative adjustment approaches yielded HRs similar to those from the primary analysis (Supplementary Table 2). The sensitivity analysis adjusting for epidemic phase bias considered multiple scenarios, which suggested that the risks of all considered COVID-19 severity outcomes might be slightly lower for AY.4.2 compared to non-AY.4.2 delta cases (Supplementary Tables 3 and 4), consistent with the primary analysis.

DISCUSSION

Based on record linkage of sequencing-confirmed COVID-19 cases in England, we found that the risks of hospitalization and mortality outcomes were similar or lower for cases infected with the AY.4.2 compared to non-AY.4.2 sublineages of the delta variant of SARS-CoV-2. The results were similar when restricted to symptomatic and likely symptomatic cases, or to vaccinated or unvaccinated subgroups, or after additional adjustment for time since second vaccine dose. Further sensitivity analyses to adjust for the effect of epidemic phase bias [3] consistently suggested that the risks of the hospitalization outcomes are similar or lower for AY.4.2 than non-AY.4.2 delta cases.

Strengths of this analysis include the use of timely population datasets that cover all hospitalization events and deaths for COVID-19 cases in England. Limitations include reporting delays of the outcome events, which may differ over time and by hospital trust. However, after stratification for calendar period and area, the reporting delays should not differ systematically by sublineage. A further limitation is the restriction to cases confirmed through sequencing, due to a lack of other methods capable of distinguishing different delta sublineages. During the study period, the median daily sequencing coverage of new COVID-19 cases was 16.5% (range, 6.5%–27.2%) [1]. More severe cases with higher viral loads may be preferentially selected for sequencing, which may restrict the generalizability of the findings. However, similar cycle threshold counts were reported between individuals infected with AY.4.2 or non-AY.4.2 identified in the REACT-1 random testing survey [4]. Hence, there is no reason to expect that such selection differed systematically by sublineage.

Several variants of the SARS-CoV-2 virus have evolved during the COVID-19 pandemic of 2020–2022. In England, the alpha (Pango lineage B.1.1.7) variant was detected in November 2020 and was found to be associated with higher transmissibility [5], and higher risks of hospital admission [6, 7] and mortality [6, 8], than previously circulating wild-type SARS-CoV-2. In March 2021, the delta variant was detected in England and soon became the dominant variant in the country. Delta is associated with higher transmissibility [9], partial vaccine escape [10, 11], and higher risk of hospitalization [2, 10, 12] and mortality [12], compared to the alpha variant. Recently, cases with AY.4.2 were reported to be less likely to experience symptomatic disease than cases with other delta sublineages [4]. Although our results indicated similar proportions with symptomatic

| Outcome | AY.4.2, n/N (%) | Non-AY.4.2 Delta, n/N (%) | HR (95% CI), AY.4.2 vs Non-AY.4.2 Delta |
|---------|----------------|---------------------------|----------------------------------------|
| Hospital admission within 14 d after specimen | 415/28736 (1.4) | 107/66/492301 (2.2) | 0.86 (0.60–0.72) | 0.85 (0.77–0.94) |
| Hospital admission or emergency care attendance within 14 d after specimen | 847/28736 (2.9) | 198/90/492301 (4.0) | 0.73 (0.68–0.79) | 0.87 (0.81–0.94) |
| COVID-19 death within 28 d after specimen | 143/28736 (0.50) | 3465/492301 (0.70) | 0.71 (0.60–0.84) | 0.85 (0.71–1.03) |
| Death due to any cause within 28 d after specimen | 165/28736 (0.57) | 3940/492301 (0.80) | 0.72 (0.61–0.84) | 0.82 (0.69–0.98) |

*Stratification for week of specimen and lower tier local authority of residence; regression adjustment for date of specimen (linear), age (restricted cubic splines with 4 knots), index of multiple deprivation rank (restricted cubic splines with 4 knots), sex, ethnicity (white, Asian, black, other/mixed/unknown), vaccination status at date of positive test (unvaccinated, <21 days since first dose, ≥21 days since first dose and < 14 days since second dose, ≥14 days since second dose) and international travel within 14 days before positive test.
BRIEF REPORT

Symptomatic or likely symptomatic cases and its sublineages. Similar to the emergence of the AY.4.2 delta sublineage, an omicron sublineage (BA.2) with a potential transmission advantage has recently been identified [1]. The findings in our study highlight the importance of assessing severity differences between SARS-CoV-2 variant sublines, and provide a baseline for future research on the relative severity between delta or delta variant sublines and other circulating variants such as omicron and its sublines.

Table 2. Hospitalization and Mortality Outcomes for COVID-19 Cases Infected With AY.4.2 Compared to Non-AY.4.2 Delta Variants, by Subgroups

| Outcome                                                   | AY.4.2, n/N (%) | Non-AY.4.2 Delta, n/N (%) | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
|-----------------------------------------------------------|----------------|---------------------------|------------------------|----------------------|
| Symptomatic or likely symptomatic cases                   |                |                           |                        |                      |
| Hospital admission within 14 d after specimen             | 415/16305 (2.5)| 10766/288776 (3.7)       | 0.68 (0.61–0.75)       | 0.89 (0.80–0.98)     |
| Hospital admission or emergency care attendance within 14 d after specimen | 847/16305 (5.2) | 19808/288776 (6.9) | 0.75 (0.70–0.80) | 0.90 (0.84–0.97) |
| COVID-19 death within 28 d after specimen                 | 143/16305 (0.88)| 3465/288776 (1.2)     | 0.73 (0.62–0.86)       | 0.97 (0.80–1.17)     |
| Death due to any cause within 28 d after specimen         | 161/16305 (0.99)| 3886/288776 (1.3)      | 0.73 (0.63–0.86)       | 0.92 (0.76–1.10)     |
| Unvaccinated or with <21 d since first vaccine dose       |                |                           |                        |                      |
| Hospital admission within 14 d after specimen             | 128/13520 (0.95)| 4310/235971 (1.8)       | 0.52 (0.43–0.61)       | 0.79 (0.65–0.95)     |
| Hospital admission or emergency care attendance within 14 d after specimen | 326/13520 (2.4) | 8807/235971 (3.7) | 0.64 (0.57–0.72) | 0.90 (0.80–1.01) |
| COVID-19 death within 28 d after specimen                 | 26/13520 (0.19) | 819/235971 (0.35) | 0.55 (0.38–0.82) | 0.77 (0.46–1.30) |
| Death due to any cause within 28 d after specimen         | 27/13520 (0.20) | 896/235971 (0.38) | 0.53 (0.36–0.77) | 0.67 (0.40–1.10) |
| ≥21 d since first vaccine dose (with or without a second vaccine dose) |              |                           |                        |                      |
| Hospital admission within 14 d after specimen             | 287/15216 (1.9)| 6456/256330 (2.5)       | 0.75 (0.66–0.84)       | 0.89 (0.79–1.01)     |
| Hospital admission or emergency care attendance within 14 d after specimen | 521/15216 (3.4)| 11001/256330 (4.3) | 0.79 (0.73–0.87) | 0.87 (0.79–0.95) |
| COVID-19 death within 28 d after specimen                 | 117/15216 (0.77)| 2646/256330 (1.0)      | 0.75 (0.62–0.90)       | 0.89 (0.72–1.10)     |
| Death due to any cause within 28 d after specimen         | 138/15216 (0.91)| 3044/256330 (1.2)      | 0.76 (0.64–0.91)       | 0.86 (0.71–1.04)     |
| ≥14 d since second vaccine dose                           |                |                           |                        |                      |
| Hospital admission within 14 d after specimen             | 267/13341 (2.0)| 5928/201625 (2.9)       | 0.68 (0.60–0.76)       | 0.87 (0.76–0.99)     |
| Hospital admission or emergency care attendance within 14 d after specimen | 475/13341 (3.6)| 9674/201625 (4.8) | 0.74 (0.67–0.81) | 0.85 (0.78–0.94) |
| COVID-19 death within 28 d after specimen                 | 113/13341 (0.85)| 2535/201625 (1.3)      | 0.67 (0.56–0.81)       | 0.88 (0.71–1.10)     |
| Death due to any cause within 28 d after specimen         | 133/13341 (1.0)| 2916/201625 (1.4)      | 0.69 (0.58–0.82)       | 0.85 (0.70–1.03)     |

Notes

1. Stratification for week of specimen and lower tier local authority of residence; regression adjustment for date of specimen (linear), age (restricted cubic splines with 4 knots), index of multiple deprivation rank (restricted cubic splines with 4 knots), sex, ethnicity (white, Asian, black, others/mixed/unknown), vaccination status at date of positive test (unvaccinated, <21 days since first dose, ≥21 days since first dose and <14 days since second dose, ≥14 days since second dose) and international travel within 14 days before positive test.

2. Cases who (1) were recorded to be symptomatic at the time of positive test, (2) were hospitalized, attended emergency care, or died with COVID-19 mentioned on the death certificate, or (3) were tested through the pillar 1 hospital testing program. See Supplementary Material for a justification of this definition.

Supplementary Data

Supplementary materials are available at The Journal of Infectious Diseases online. Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Author contributions. T. N., K. H., A. Z., S. R. S., N. A., S. G. N., A. C., S. T., D. D. A., G. D., and A. M. P. contributed to the design of the study. K. H., A. Z., S. G. N., A. C., J. L. B., R. M., N. G., E. G., S. G., M. C., S. T., and G. D. contributed to data collection and creation of data resources. T. N. performed the statistical analysis, with support from S. R. S., D. D. A., and A. M. P. Funding was acquired by A. M. P., A. C., and D. D. A. The first draft of the manuscript was written by T. N., and A. M. P. supwriting. T. N., K. H., A. Z., S. R. S., S. G. N., A. C., S. T., D. D. A., G. D., and A. M. P. contributed to the writing of a revised draft. All authors critically reviewed and edited the final manuscript. All authors approved the final version of the manuscript and agree to be accountable for the work.

Disclaimer. The funders played no direct role in the study. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Financial support. This work was supported by the United Kingdom Research and Innovation Medical Research Council (UKRI MRC) (unit programme numbers MC_UU_00002/11 to D. D. A. and A. M. P., and MC_UU_00002/10 to S. R. S.); UKRI MRC/Department of Health and Social Care National Institute for Health Research (NIHR) COVID-19 Rapid Response Call (grant number MC_PC_19074 to T. N., A. C., D. D. A., and A. M. P.); NIHR Health Protection Unit in Behavioural Science and Evaluation (to D. D. A.); and NIHR Cambridge Biomedical Research Centre (grant number BRC-1215-20014).

Potential conflicts of interest. G. D. declares that his employer, UK Health Security Agency, previously known as Public Health England, received funding from GlaxoSmithKline for a research project related to influenza antiviral treatment. This preceded and had no relation to COVID-19, and G. D. had no role in and received no funding from the project. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefings. https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings. Accessed 8 February 2022.
2. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis 2022; 22:35–42.
3. Seaman SR, Nyberg T, Overton CE, Pascall D, Presanis AM, De Angelis D. Adjusting for time of infection or positive test when estimating the risk of a post-infection outcome in an epidemic. medRxiv, doi: 10.1101/2021.08.13.21262014, 18 August 2021, preprint: not peer reviewed.
4. Chadeau-Hyam M, Eales O, Bodinier B, et al. REACT-1 round 15 final report: increased breakthrough SARS-CoV-2 infections among adults who had received two doses of vaccine, but booster doses and first doses in children are providing important protection. medRxiv, doi: 10.1101/2021.12.14.21267806, 16 December 2021, preprint: not peer reviewed.
5. Volz E, Mishra S, Chand M, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 2021; 593:266–9.
6. Nyberg T, Twohig KA, Harris RJ, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ 2021; 373:n1412.
7. Funk T, Pharris A, Spiteri G, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill 2021; 26:2100348.
8. Davies NG, Jarvis CI, Group CC-W, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 2021; 593:270–4.
9. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill 2021; 26:2100509.
10. Sheikh A, McMenamin J, Taylor B, Robertson C; Public Health Scotland, the EAVE II Collaborators. SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021; 397:2461–2.
11. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med 2021; 385:585–94.
12. Fisman DN, Tuite AR. Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. CMAJ 2021; 193:E1619–25.
13. Eales O, Page A, de Oliveira Martins L, et al. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of delta sub-lineages and increased transmissibility of YA.4.2. medRxiv, doi: 10.1101/2021.12.17.21267925, 17 December 2021, preprint: not peer reviewed.
14. Lassaunière R, Polacek C, Fonager J, et al. Neutralisation of the SARS-CoV-2 delta variant sub-lineages YA.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine elicited sera, Denmark, 1 to 26 November 2021. Euro Surveill 2021; 26:2101059.
15. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England. SSRN, doi: 10.2139/ssrn.4025932, 4 February 2022, preprint: not peer reviewed.